vaccinolog
defin
scienc
vaccin
histor
includ
basic
scienc
immunogen
host
immun
respons
deliveri
strategi
technolog
manufactur
clinic
evalu
recent
scienc
expand
includ
safeti
regulatori
ethic
econom
consider
vaccin
develop
utilis
veterinari
vaccin
equal
import
field
vaccinolog
contribut
anim
health
also
secur
food
suppli
human
although
tradit
vaccinolog
focus
infecti
diseas
move
forward
twentyfirst
centuri
vaccin
also
potenti
make
signific
contribut
control
noninfecti
diseas
cancer
neurodegen
diseas
addict
npj
vaccin
new
open
access
onlineonli
journal
part
natur
research
portfolio
publish
partnership
univers
texa
medic
branch
seali
center
vaccin
develop
journal
dedic
highlight
import
scientif
advanc
vaccin
research
develop
given
public
health
import
vaccin
addit
publish
highqual
origin
research
npj
vaccin
also
publish
review
perspect
commentari
editori
correspond
reader
provid
current
inform
develop
interest
vaccin
seem
though
centuri
pass
sinc
routin
experienc
childhood
diseas
polio
measl
diphtheria
haemophilu
influenza
type
b
rubella
much
societi
rememb
often
devast
impact
common
infecti
diseas
rare
ever
see
someon
crutch
result
paralyt
poliomyel
hear
defici
caus
measl
infect
owe
huge
debt
gratitud
pioneer
vaccinologist
twentieth
centuri
success
develop
vaccin
mani
lifethreaten
childhood
diseas
success
result
us
center
diseas
control
prevent
consid
vaccin
greatest
public
health
achiev
twentieth
centuri
similarli
compar
success
develop
mani
veterinari
vaccin
date
crown
glori
scienc
vaccinolog
erad
smallpox
human
rinderpest
cattl
vaccin
research
develop
chang
greatli
past
year
empir
approach
one
ration
support
basic
appli
scienc
exampl
come
mind
hepat
b
vaccin
develop
express
hepat
b
surfac
antigen
yeast
meningococc
type
b
vaccin
develop
revers
vaccinolog
tetraval
liveattenu
dengu
vaccin
develop
use
revers
genet
concurr
continu
increas
quantiti
qualiti
data
need
support
vaccin
develop
pathway
vaccin
licensur
thu
seen
move
vaccin
develop
exploit
new
technolog
regulatori
scienc
also
utilis
inform
evalu
safeti
efficaci
candid
vaccin
overal
posit
neg
effect
posit
know
far
characterist
particular
vaccin
safeti
improv
howev
bad
news
seen
correspond
increas
number
vaccin
licens
increas
knowledg
better
understand
appear
lengthen
time
taken
gener
requir
data
inform
requir
licensur
situat
unlik
chang
forese
futur
alway
ask
student
vaccinolog
class
mani
human
vaccin
usual
answer
vari
student
alway
surpris
tell
human
vaccin
licens
unit
state
europ
actual
veterinari
vaccinolog
success
stori
vaccin
licens
around
world
although
demonstr
success
develop
human
veterinari
vaccin
also
emphasis
gener
societi
understand
ongo
need
continu
develop
new
vaccin
necess
provid
resourc
research
develop
requir
addit
vaccin
situat
made
even
difficult
societi
expect
vaccin
must
effect
safe
cost
us
less
veterinari
vaccin
clearli
imposs
task
twentyfirst
centuri
progress
need
come
term
pay
vaccin
research
develop
everi
vaccin
develop
involv
molecular
techniqu
regul
continu
expand
utilis
techniqu
safeti
qualiti
control
requir
vaccin
research
develop
continu
becom
sophist
use
stateoftheart
molecular
techniqu
cost
specul
sanofi
pasteur
recent
licens
recombin
chimer
tetraval
liveattenu
dengu
vaccin
took
year
us
billion
develop
current
model
pharmaceut
compani
recoup
cost
via
price
product
yet
consum
often
prepar
pay
cost
unless
feel
person
threaten
particular
infecti
diseas
recent
year
govern
nongovernment
organis
assum
cost
doubt
vaccin
would
develop
without
support
develop
test
ebola
vaccin
one
immedi
come
mind
case
research
develop
vaccin
also
question
educ
peopl
take
vaccin
particularli
new
one
vaccin
implement
becom
increasingli
import
area
probabl
think
term
vaccin
research
develop
pathway
vaccin
research
develop
implement
pathway
twentyfirst
centuri
demonstr
use
molecular
techniqu
acquir
detail
knowledg
wwwnaturecomnpjvaccin
previous
unknown
infecti
agent
record
time
exemplifi
sever
acut
respiratori
syndrom
coronaviru
middl
east
respiratori
syndrom
coronaviru
use
inform
develop
candid
vaccin
recent
ebola
epidem
africa
demonstr
year
preclin
develop
rapidli
translat
clinic
evalu
joint
effort
funder
develop
regul
accid
lead
vaccin
candid
develop
use
molecular
techniqu
three
livevector
vaccin
recombin
vesicular
stomat
viru
recombinantmodifi
vaccinia
ankara
recombin
adenoviru
recombin
subunit
glycoprotein
vaccin
platform
technolog
demonstr
far
vaccinolog
progress
one
bugon
vaccin
gener
vaccin
platform
multipl
candid
vaccin
despit
come
long
way
short
period
time
yet
licens
human
vaccin
emerg
diseas
although
exampl
licens
veterinari
emerg
diseas
vaccin
recombin
subunit
protein
vaccin
develop
hendra
australia
recombin
vaccin
west
nile
unit
state
europ
licens
human
emerg
diseas
vaccin
part
due
transient
natur
emerg
diseas
occurr
previous
unknown
public
health
threat
prompt
immedi
respons
govern
nongovern
funder
huge
resourc
alloc
immens
effort
academia
pharmaceut
compani
govern
nongovern
scientist
occur
short
period
time
good
news
control
emerg
diseas
bad
news
success
result
loss
interest
media
control
fund
resourc
prioriti
overtak
emerg
diseas
respect
ebola
replac
zika
progress
emerg
diseas
noth
short
amaz
first
publish
report
zika
may
paper
pubm
plu
mani
other
nonpeerreview
server
ground
zero
littl
known
viru
diseas
mous
nonhuman
primat
model
preclin
develop
vaccin
candid
discoveri
preclin
develop
strong
likelihood
phase
clinic
trial
end
excel
exampl
academia
pharmaceut
compani
govern
nongovern
scientist
plu
regul
funder
work
togeth
doubt
emerg
diseas
continu
public
health
threat
futur
somehow
need
avoid
kneejerk
respons
one
approach
would
creat
intern
centr
excel
emerg
diseas
research
guarante
fund
whose
role
would
undertak
research
develop
vaccin
diseas
centr
would
need
publicpriv
partnership
rather
product
develop
partnership
definit
know
emerg
diseas
becom
public
health
threat
vaccin
research
develop
need
basic
appli
scienc
expertis
also
expertis
pharmaceut
compani
scaleup
manufactur
shown
ebola
epidem
littl
need
routin
vaccin
mani
emerg
diseas
major
effort
stockpil
vaccin
replenish
end
shelf
life
use
approach
limit
interest
larg
vaccin
pharmaceut
compani
due
low
return
invest
move
forward
twentyfirst
centuri
also
becom
evid
human
anim
respond
vaccin
way
individu
strong
immun
respons
wherea
other
weak
even
undetect
respons
similarli
reactogen
particular
vaccin
vari
individu
level
mani
differ
due
host
respons
vaccin
despit
learn
much
host
innat
adapt
immun
respons
vaccin
popul
level
understand
somewhat
rudimentari
individu
level
although
clear
genet
factor
role
respons
individu
vaccin
much
learn
area
system
vaccinolog
includ
genom
proteom
transcriptom
informat
etc
becom
increasingli
import
futur
bridg
basic
clinic
scienc
provid
inform
safeti
immunogen
furthermor
inform
eventu
enabl
particular
vaccin
avail
differ
formul
base
genet
background
host
may
appear
econom
viabl
present
time
chang
futur
concurr
utilis
appropri
adjuv
altern
rout
deliveri
particular
vaccin
provid
great
opportun
improv
efficaci
vaccin
futur
move
twentyfirst
centuri
infecti
diseas
vaccin
research
focus
difficult
childhood
diseas
applic
childhood
vaccin
adult
elderli
goal
enabl
adult
live
longer
howev
infecti
diseas
primari
caus
morbid
mortal
adult
world
health
organ
identifi
chronic
diseas
lead
caus
disabl
worldwid
although
possibl
time
develop
prophylact
vaccin
diseas
develop
therapeut
vaccin
lead
opportun
manag
diseas
earli
stage
exampl
diseas
includ
cancer
obes
neurodegen
diseas
addict
atherosclerosi
vaccin
would
expect
extend
life
expect
adult
reduc
burden
diseas
present
time
research
discoveri
stage
similar
infecti
diseas
vaccin
research
twentieth
centuri
correct
golden
year
noninfecti
diseas
vaccin
research
ahead
us
much
focu
far
therapeut
administr
antibodi
particular
monoclon
antibodi
approach
promis
success
infecti
diseas
notabl
exampl
would
respiratori
syncyti
viru
develop
thirdgener
humanis
monoclon
antibodi
one
dose
give
protect
month
clear
applic
noninfecti
diseas
one
surpris
aspect
noninfecti
diseas
vaccin
research
appar
lack
collabor
infecti
diseas
vaccin
expertis
work
noninfecti
diseas
vaccin
interdisciplinari
collabor
would
predict
acceler
noninfecti
diseas
vaccin
research
develop
goal
npj
vaccin
highlight
import
scientif
advanc
human
veterinari
vaccin
research
develop
multidisciplinari
journal
dedic
publish
finest
highqual
research
develop
human
veterinari
vaccin
includ
discoveri
basic
scienc
nonclin
develop
vaccin
clinic
evalu
vaccin
vaccin
safeti
regulatori
scienc
first
articl
provid
import
new
inform
emerg
diseas
vaccin
two
henipavirus
one
veterinari
vaccin
hendra
human
vaccin
nipah
addit
review
current
statu
vaccin
develop
zika
also
interest
paper
investig
head
stalk
antibodi
polyclon
sera
obtain
healthcar
worker
follow
vaccin
monoval
pandem
influenza
vaccin
associ
comment
encourag
high
qualiti
content
paper
receiv
editori
